Pharmaceutical

Bard ordered to pay $3.6 million over defective transvaginal mesh

mesh Bard ordered to pay $3.6 million over defective transvaginal meshC.R. Bard was slapped with a $3.6 million verdict in the first lawsuit to go to trial involving the medical device manufacturer’s allegedly defective transvaginal mesh. The ruling comes just months after the company agreed to settle thousands of other lawsuits from women who claim to have been injured by the transvagainal mesh.

The jury had awarded the plaintiff in the case $5.5 million in damages, but the court slashed the award to $3.6 million after finding some fault with the doctor who had implanted the plaintiff with the company’s Avaulta transvaginal mesh.

Transvaginal mesh, also known as bladder sling, is a type of surgical mesh that is used to treat common pelvic floor disorders including stress urinary incontinence and pelvic organ prolapse. The mesh is implanted through the vagina to hold up organs that have dropped due to childbirth, obesity or age.

Transvaginal mesh is manufactured by dozens of medical device companies. The mesh has been linked to serious complications including the mesh eroding into tissue or protruding into organs causing chronic pain, disability, infections, and incontinence.

Earlier this year, Bard agreed to pay more than $200 million to settle 3,000 lawsuits filed by women who claimed to have suffered transvaginal mesh injuries, resolving about a fifth of the outstanding lawsuits against Bard’s transvaginal mesh devices. In October 2014, Bard agreed to pay $21 million to settle 500 lawsuits involving its transvaginal mesh.

Tens of thousands of lawsuits have been filed against manufacturers of transvaginal mesh, including Johnson & Johnson and Boston Scientific. In March 2014, Coloplast paid $16 million to resolve lawsuits over its defective mesh.

Source: Fierce Medical Devices